Skip to main content

Advertisement

SpringerLink
Log in

Assessing response to osteoporosis therapy

  • Special Feature
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Patients treated with pharmacological agents to improve bone strength and reduce fracture risk may not achieve optimal skeletal benefit for reasons that include poor compliance and persistence, inadequate calcium and vitamin D intake, malabsorption, and medications or co-morbidities with adverse skeletal effects. Monitoring the effects of therapy can inform the patient and physician that the drug is having its expected skeletal response. Treatment is often monitored with serial bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry or bone turnover markers (BTMs). Stable or increasing BMD is associated with reduced fracture risk in clinical trials, and is considered an indication of good response to therapy in individual patients outside of clinical trials. There are many differences between subjects in clinical trials and patients being treated in clinical practice. Thus, although defining a clinical practice patient as a “nonresponder” or “suboptimal responder” to treatment is problematic, a pragmatic approach would be to consider evaluation for contributing factors and possible changes in therapy in patients who have a statistically significant decrease in BMD, do not have the expected change in BTMs, or have a fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kanis JA, on behalf of the World Health Organization Scientific Group (2007) (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield.

  2. Lotz JC, Cheal EJ, Hayes WC (1991) Fracture prediction for the proximal femur using finite element models: Part I–Linear analysis. J Biomechan Eng 113:353–360

    Article  CAS  Google Scholar 

  3. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    PubMed  CAS  Google Scholar 

  4. Kanis JA, the WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Osteoporos Int 4:368–381

    Article  PubMed  CAS  Google Scholar 

  5. Cranney A, Tugwell P, Wells G, Guyatt G (2002) Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev 23:497–507

    CAS  Google Scholar 

  6. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231–236

    Article  PubMed  CAS  Google Scholar 

  7. Mazess R, Chesnut CH III, McClung M, Genant H (1992) Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int 51:14–17

    Article  PubMed  CAS  Google Scholar 

  8. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM (2006) Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9:4–14

    Article  PubMed  Google Scholar 

  9. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213

    PubMed  Google Scholar 

  10. US Department of Health and Human Services (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General.

  11. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031

    Article  PubMed  CAS  Google Scholar 

  12. Diez-Perez A, Gonzalez-Macias J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int DOI 10.1007/s00198-008-0659-2

  13. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  PubMed  CAS  Google Scholar 

  14. Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:1531–1538

    Article  PubMed  CAS  Google Scholar 

  15. Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536

    Article  PubMed  CAS  Google Scholar 

  16. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, PROOF Study Group (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276

    Article  PubMed  CAS  Google Scholar 

  17. Watts NB, Miller PMR, Chen P, Arsenault J, Krohn K (2008) Vertebral fracture risk is reduced for women who lose femoral neck bone mineral density during teriparatide therapy [abstract]. J Clin Densitom 11:In press

  18. Chapurlat RD, Palermo L, Ramsay P, Cummings SR, The Fracture Intervention Trial (2005) Risk of fracture among women who lose bone density during treatment with alendronate. Osteoporos Int 16:842–848

    Article  PubMed  CAS  Google Scholar 

  19. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, Silverman S (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference. J Clin Densitom 11:75–91

    Article  PubMed  Google Scholar 

  20. Lewiecki EM, Rudolph LA (2002) How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 17(Suppl 2):S367

    Google Scholar 

  21. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258

    Article  PubMed  Google Scholar 

  22. Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307–314

    Article  PubMed  Google Scholar 

  23. Del Puente A, Scognamiglio A, Itto E, Ferrara G, Oriente P (2000) Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27:1980–1983

    PubMed  Google Scholar 

  24. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565–1570

    Article  PubMed  CAS  Google Scholar 

  25. Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6

    Article  PubMed  Google Scholar 

  26. Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Papaioannou A, Goldsmith CH (2003) What predicts early fracture or bone loss on bisphosphonate therapy? J Clin Densitom 6:315–322

    Article  PubMed  Google Scholar 

  27. Jakob F, Marin F, Martin-Mola E, Torgerson D, Fardellone P, Adami S, Thalassinos NC, Sykes D, Melo-Gomes J, Chinn C, Nicholson T, Cooper C (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 99:531–543

    Article  PubMed  CAS  Google Scholar 

  28. Obermayer-Pietsch B, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Anastasilakis A, McCloskey E (2006) Response of BMD to 24 months of teriparatide (rhPTH 1–34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS study. J Bone Miner Res 21(Suppl 1):S43

    Google Scholar 

  29. NICE (National Institute for Clinical Excellence) (2004) Final appraisal determination- secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE:

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM, 87106, USA

    E. M. Lewiecki

  2. University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, OH, USA

    N. B. Watts

Authors
  1. E. M. Lewiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. B. Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. M. Lewiecki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewiecki, E.M., Watts, N.B. Assessing response to osteoporosis therapy. Osteoporos Int 19, 1363–1368 (2008). https://doi.org/10.1007/s00198-008-0661-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-008-0661-8

Keywords

Search

Navigation